EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $20.73, up 2.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EYPT shares have gain 2.27% over the last week, with a monthly amount drifted -18.10%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists. In a post published today on Yahoo Finance, – Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board –.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on January 22, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $35. Previously, Mizuho started tracking the stock with Buy rating on November 02, 2023, and set its price target to $20. On April 21, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $33 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $21 on July 07, 2022. Cowen initiated its recommendation with a Outperform and recommended $25 as its price target on March 01, 2021. Cantor Fitzgerald started tracking with a Overweight rating for this stock on January 28, 2021, and assigned it a price target of $22. In a note dated April 06, 2020, B. Riley FBR downgraded an Neutral rating on this stock and revised its target price from $4 to $1.
EyePoint Pharmaceuticals Inc [EYPT] stock has fluctuated between $2.95 and $30.99 over the past year. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $20.73 at the most recent close of the market. An investor can expect a potential return of 20.6% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] reported sales of 46.02M for the trailing twelve months, which represents a growth of 33.18%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.63%, Pretax Profit Margin comes in at -1.54%, and Net Profit Margin reading is -1.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.62 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.22 points at the first support level, and at 19.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.19, and for the 2nd resistance point, it is at 21.64.
EyePoint Pharmaceuticals Inc [EYPT] reported earnings per share of -$0.33 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.49/share, meaning a difference of $0.16 and a surprise factor of 32.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.33 per share as compared to estimates of -$0.51 per share, a difference of $0.18 representing a surprise of 35.30%.
Ratios To Look Out For
For context, EyePoint Pharmaceuticals Inc’s Current Ratio is 5.45. In addition, the Quick Ratio stands at 5.39 and the Cash Ratio stands at 4.45. Considering the valuation of this stock, the price to sales ratio is 22.45, the price to book ratio is 3.82.
Transactions by insiders
Recent insider trading involved Jones David Scott, SVP & Chief Commercial Officer, that happened on Feb 02 ’24 when 209.0 shares were sold. Chief Medical Officer, Paggiarino Dario A. completed a deal on Jan 26 ’24 to sell 49325.0 shares. Meanwhile, SVP & Chief Commercial Officer Jones David Scott sold 26017.0 shares on Jan 26 ’24.
